Keyphrases
Acute Myeloid Leukemia
96%
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
46%
Venetoclax
40%
Newly Diagnosed
39%
Chronic Myeloid Leukemia
35%
Phase II Study
34%
Myelofibrosis
28%
Complete Remission
26%
Hypomethylating Agents
23%
Overall Survival
23%
Relapsed or Refractory
22%
Myelodysplastic Syndrome
22%
Relapsed or Refractory Acute Myeloid Leukemia
22%
CD123
21%
Ruxolitinib
20%
Myeloproliferative Neoplasms
19%
Tagraxofusp
19%
Decitabine
17%
Intensive Chemotherapy
16%
Older Patients
15%
Azacitidine
15%
Phase II Trial
14%
Median Overall Survival
14%
Cytarabine
13%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
12%
FMS-like Tyrosine Kinase 3 (FLT3)
12%
Tyrosine Kinase Inhibitor
11%
Polycythemia Vera
11%
Targeted Therapy
11%
Hematological Malignancies
11%
Frontline Therapy
11%
High Risk
11%
Leukemia
10%
Single Center
10%
Dasatinib
10%
Cyclophosphamide
10%
Monotherapy
9%
Clinical Outcomes
9%
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
9%
Event-free Survival
9%
Leukemia Patients
9%
Ponatinib
9%
Clinical Trials
9%
Bone Marrow
8%
Complete Response
8%
Hyperfractionated
8%
FLT3 Inhibitor
8%
Cladribine
8%
Idarubicin
8%
Chemotherapy
8%
Medicine and Dentistry
Acute Myeloid Leukemia
86%
Neoplasm
53%
Plasmacytoid Dendritic Cell
45%
Venetoclax
37%
Overall Survival
33%
Diseases
32%
Myeloproliferative Neoplasm
30%
Myelofibrosis
29%
Hypomethylating Agent
22%
Myelodysplastic Syndrome
22%
Clinical Trial
18%
Ruxolitinib
16%
Acute Lymphoblastic Leukemia
15%
Chronic Myelogenous Leukemia
14%
Polycythemia vera
14%
Azacitidine
14%
Tagraxofusp
13%
Philadelphia 1 Chromosome
13%
Tyrosine-Kinase Inhibitor
13%
Arm
13%
Decitabine
12%
Chronic Myelomonocytic Leukemia
12%
Targeted Therapy
11%
Oncology
11%
Cytarabine
11%
Leukemia
11%
Adolescence
11%
Acute Myelogenous Leukemia
11%
Janus Kinase Inhibitor
11%
Cancer
10%
Malignant Neoplasm
10%
Hematologic Malignancy
10%
Minimal Residual Disease
10%
Hematology
9%
Adverse Event
9%
Event Free Survival
9%
Monotherapy
8%
Vincristine
8%
Ponatinib
7%
Dexamethasone
7%
Cyclophosphamide
7%
Low Drug Dose
7%
Doxorubicin
7%
Myeloid Leukemia
7%
Myeloid Malignancy
7%
Pediatrics
6%
Cladribine
6%
B-Cell Chronic Lymphocytic Leukemia
6%
Janus Kinase
5%
Combination Therapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Neoplasm
41%
Venetoclax
41%
Overall Survival
38%
Remission
34%
Chemotherapy
32%
Myelofibrosis
30%
Myelodysplastic Syndrome
26%
Diseases
24%
Cytarabine
24%
Clinical Trial
21%
Azacitidine
20%
Ruxolitinib
19%
Acute Lymphoblastic Leukemia
19%
Tagraxofusp
18%
Decitabine
18%
Chronic Myeloid Leukemia
16%
Adverse Event
14%
Myeloproliferative Neoplasm
14%
Protein Tyrosine Kinase Inhibitor
12%
Polycythemia vera
12%
Philadelphia 1 Chromosome
12%
Minimal Residual Disease
11%
Leukemia
11%
Chronic Myelomonocytic Leukemia
10%
Idarubicin
9%
Malignant Neoplasm
9%
Monotherapy
9%
Vincristine
9%
Event Free Survival
9%
Dexamethasone
9%
Cyclophosphamide
9%
Janus Kinase Inhibitor
8%
Myeloid Leukemia
8%
Hematologic Malignancy
8%
Fludarabine
7%
Dasatinib
7%
Cladribine
7%
Ponatinib
7%
Doxorubicin
7%
Secondary Acute Myeloid Leukemia
6%
Clofarabine
6%
Core Binding Factor
5%
Fibrosis
5%
Combination Therapy
5%
Gemtuzumab Ozogamicin
5%
Inotuzumab Ozogamicin
5%